Art. -Nr.: HY-10227

Bortezomib

(Synonyms: PS-341; LDP-341; NSC 681239)

261 Cited Publications

Kundenbewertung

Based on 261 publication(s) in Google Scholar

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.80%
CAS. Nr.: 179324-69-7
Formel: C₁₉H₂₅BN₄O₄
Molecular Weight:384.24

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Bortezomib Chemical Structure

CAS. Nr.: 179324-69-7

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (261)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM)^[1]^[2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs)^[7].

IC₅₀ & Target

20S proteasome subunit β5

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle TREM receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
5TGM1	IC₅₀	6.78 nM Compound: PS-341, Bortezomib	Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay	[PMID: 24119559]
786-0	GI₅₀	1.44 nM Compound: Bortezomib, Velcade	Growth inhibition of human 786-0 cells Growth inhibition of human 786-0 cells	[PMID: 24946214]
A2780	IC₅₀	1.7 nM Compound: 1, bortezomib	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 18247547]
A2780	IC₅₀	28.9 nM Compound: Bortezomib	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 28182990]
A-431	IC₅₀	28.2 nM Compound: Bortezomib	Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
A498	GI₅₀	0.48 nM Compound: Bortezomib, Velcade	Growth inhibition of human A498 cells Growth inhibition of human A498 cells	[PMID: 24946214]
A549	IC₅₀	255 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19537716]
A549	IC₅₀	6.7 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20158184]
A549	IC₅₀	13.9 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21077681]
A549	GI₅₀	3.09 nM Compound: Bortezomib, Velcade	Growth inhibition of human A549/ATCC cells Growth inhibition of human A549/ATCC cells	[PMID: 24946214]
A549	IC₅₀	2135.73 nM Compound: PS-341	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27769033]
A549	IC₅₀	2.5 nM Compound: Bortezomib	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 28182990]
A549	IC₅₀	92 nM Compound: BTZ	Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
A549	IC₅₀	2.14 μM Compound: Bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28634039]
A549	IC₅₀	9.318 μM Compound: Bortezomib	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 29426629]
A549	IC₅₀	0.62 μM Compound: Bortezomib	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
ACHN	GI₅₀	0.79 nM Compound: Bortezomib, Velcade	Growth inhibition of human ACHN cells Growth inhibition of human ACHN cells	[PMID: 24946214]
ARH-77	IC₅₀	6.07 nM Compound: Bortezomib	Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay	[PMID: 26965867]
ARH-77	IC₅₀	9.57 nM Compound: Bortezomib	Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
BEL-7404 tumor cell line	IC₅₀	25.04 nM Compound: PS-341	Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 27769033]
BGC-823	IC₅₀	880 nM Compound: bortezomib	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19537716]
BGC-823	IC₅₀	2890 nM Compound: Bortezomib	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19747832]
BT-549	GI₅₀	0.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human BT549 cells Growth inhibition of human BT549 cells	[PMID: 24946214]
BXPC-3	IC₅₀	11.8 nM Compound: Bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19747832]
BXPC-3	IC₅₀	16.2 nM Compound: bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 20158184]
BXPC-3	IC₅₀	19.4 nM Compound: bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 21077681]
CAKI-1	GI₅₀	0.66 nM Compound: Bortezomib, Velcade	Growth inhibition of human CAKI-1 cells Growth inhibition of human CAKI-1 cells	[PMID: 24946214]
CAL-27	IC₅₀	4.73 μM Compound: BTZ	Antiproliferative activity against human CAL-27 cells overexpressing HDAC4 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells overexpressing HDAC4 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
CAL-27	IC₅₀	7.6 μM Compound: BTZ	Antiproliferative activity against human CAL-27 cells without HDAC4 expression assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells without HDAC4 expression assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
Calu-6	IC₅₀	3.9 nM Compound: Bortezomib	Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay	10.1039/C2MD20060K
CCRF-CEM	GI₅₀	0.35 nM Compound: Bortezomib, Velcade	Growth inhibition of human CCRF-CEM cells Growth inhibition of human CCRF-CEM cells	[PMID: 24946214]
CCRF-CEM	IC₅₀	11 nM Compound: Bortezomib	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
CCRF-CEM	GI₅₀	0.001 μM Compound: Bortezomib	Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
COLO 205	GI₅₀	1.23 nM Compound: Bortezomib, Velcade	Growth inhibition of human COLO205 cells Growth inhibition of human COLO205 cells	[PMID: 24946214]
DLD-1	IC₅₀	0.0002 μM Compound: Bortezomib, Velcade, PS-341	Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DLD-1	IC₅₀	0.0009 μM Compound: Bortezomib, Velcade, PS-341	Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DLD-1	IC₅₀	0.2 nM Compound: Bortezomib, Velcade, PS-341	Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DLD-1	IC₅₀	0.9 nM Compound: Bortezomib, Velcade, PS-341	Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DU-145	GI₅₀	1.7 nM Compound: Bortezomib, Velcade	Growth inhibition of human DU145 cells Growth inhibition of human DU145 cells	[PMID: 24946214]
EA.hy 926	IC₅₀	0.09 μM Compound: Bortezomib	Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
EKVX	GI₅₀	3.02 nM Compound: Bortezomib, Velcade	Growth inhibition of human EKVX cells Growth inhibition of human EKVX cells	[PMID: 24946214]
GES1	IC₅₀	12.6 nM Compound: PS-341	Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HCC 2998	GI₅₀	0.6 nM Compound: Bortezomib, Velcade	Growth inhibition of human HCC2998 cells Growth inhibition of human HCC2998 cells	[PMID: 24946214]
HCT-116	IC₅₀	0.01 μM Compound: bortezomib	Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 23547757]
HCT-116	IC₅₀	5 nM Compound: bortezomib	Inhibition of human HCT116 cell growth Inhibition of human HCT116 cell growth	[PMID: 24524217]
HCT-116	GI₅₀	0.6 nM Compound: Bortezomib, Velcade	Growth inhibition of human HCT116 cells Growth inhibition of human HCT116 cells	[PMID: 24946214]
HCT-116	IC₅₀	27 nM Compound: Bortezomib	Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
HCT-116	IC₅₀	1.4 nM Compound: PS-341	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27769033]
HCT-116	IC₅₀	0.001 μM Compound: Bortezomib	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28634039]
HCT-15	GI₅₀	1.51 nM Compound: Bortezomib, Velcade	Growth inhibition of human HCT15 cells Growth inhibition of human HCT15 cells	[PMID: 24946214]
HEK293	IC₅₀	10 nM Compound: 1, bortezomib	Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay	[PMID: 20875739]
HEK293	IC₅₀	0.014 μM Compound: PS-341	Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay	[PMID: 21044847]
HEK293	CC₅₀	347 nM Compound: 1a, Bortezomib	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 21634429]
HEK293	IC₅₀	27 nM Compound: 1a, Bortezomib	Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader	[PMID: 21634429]
HEK293	IC₅₀	14 μM Compound: Bortezomib	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition Cytotoxicity against human HEK293 cells assessed as cell growth inhibition	[PMID: 33333398]
HEK293	IC₅₀	9.7 nM Compound: Bortezomib	Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control	10.1039/C2MD20060K
HEK-293T	IC₅₀	12 nM Compound: BTZ	Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
HeLa	IC₅₀	0.02 μM Compound: PS-341	Growth inhibition of human HeLa cells after 72 hrs by MTT assay Growth inhibition of human HeLa cells after 72 hrs by MTT assay	[PMID: 19428245]
HeLa	IC₅₀	92 nM Compound: bortezomib	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19537716]
HeLa	GI₅₀	168.1 μM Compound: BTZ; Product S4	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32031798]
HeLa	IC₅₀	>200 nM Compound: Btz	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	20 nM Compound: Btz	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HepG2	IC₅₀	37.5 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19537716]
HepG2	IC₅₀	7.5 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20158184]
HepG2	IC₅₀	25.2 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21077681]
HepG2	IC₅₀	1.61 nM Compound: PS-341	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27769033]
HepG2	EC₅₀	0.01 μM Compound: Bortezomib	Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29800827]
HepG2	GI₅₀	100.6 μM Compound: BTZ; Product S4	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32031798]
HepG2	EC₅₀	0.013 μM Compound: BTZ	Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay	[PMID: 36608337]
HET-1A	IC₅₀	25.6 nM Compound: PS-341	Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HL-60	ED₅₀	2.5 nM Compound: bortezomib	Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins	[PMID: 19422206]
HL-60	IC₅₀	5.5 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19537716]
HL-60	IC₅₀	6.9 nM Compound: Bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19747832]
HL-60	IC₅₀	7.1 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20158184]
HL-60	IC₅₀	3.5 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 21077681]
HL-60	ED₅₀	0.0025 μM Compound: Bortezomib	Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay	[PMID: 21973101]
HL-60	IC₅₀	7.6 nM Compound: PS-341	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27769033]
HL-60	IC₅₀	3.2 nM Compound: Bortezomib	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 28182990]
HL-60	IC₅₀	0.008 μM Compound: Bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28634039]
HL-60(TB)	GI₅₀	1.9 nM Compound: Bortezomib, Velcade	Growth inhibition of human HL-60(TB) cells Growth inhibition of human HL-60(TB) cells	[PMID: 24946214]
HOP-62	GI₅₀	4.47 nM Compound: Bortezomib, Velcade	Growth inhibition of human HOP62 cells Growth inhibition of human HOP62 cells	[PMID: 24946214]
HOP-92	GI₅₀	1 nM Compound: Bortezomib, Velcade	Growth inhibition of human HOP92 cells Growth inhibition of human HOP92 cells	[PMID: 24946214]
Hs-578T	GI₅₀	1.02 nM Compound: Bortezomib, Velcade	Growth inhibition of human Hs 578T cells Growth inhibition of human Hs 578T cells	[PMID: 24946214]
HT-29	ED₅₀	>20 μM Compound: Bortezomib	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	GI₅₀	0.95 nM Compound: Bortezomib, Velcade	Growth inhibition of human HT-29 cells Growth inhibition of human HT-29 cells	[PMID: 24946214]
HT-29	IC₅₀	3.2 nM Compound: Btz	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HUVEC	IC₅₀	11.2 nM Compound: PS-341	Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
IGROV-1	GI₅₀	2.24 nM Compound: Bortezomib, Velcade	Growth inhibition of human IGROV1 cells Growth inhibition of human IGROV1 cells	[PMID: 24946214]
K562	GI₅₀	1.17 nM Compound: Bortezomib, Velcade	Growth inhibition of human K562 cells Growth inhibition of human K562 cells	[PMID: 24946214]
K562	GI₅₀	0.007 μM Compound: Bortezomib	Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
KB	IC₅₀	59.5 nM Compound: bortezomib	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19537716]
KM12	GI₅₀	1.7 nM Compound: Bortezomib, Velcade	Growth inhibition of human KM12 cells Growth inhibition of human KM12 cells	[PMID: 24946214]
KM3/BTZ	IC₅₀	226 nM Compound: PS-341	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
L02	IC₅₀	55.5 nM Compound: PS-341	Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
LOX IMVI	GI₅₀	0.78 nM Compound: Bortezomib, Velcade	Growth inhibition of human LOXIMVI cells Growth inhibition of human LOXIMVI cells	[PMID: 24946214]
M14	GI₅₀	0.93 nM Compound: Bortezomib, Velcade	Growth inhibition of human M14 cells Growth inhibition of human M14 cells	[PMID: 24946214]
Malme-3M	GI₅₀	0.45 nM Compound: Bortezomib, Velcade	Growth inhibition of human MALME-3M cells Growth inhibition of human MALME-3M cells	[PMID: 24946214]
MCF7	GI₅₀	0.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 24946214]
MCF7	IC₅₀	0.025 μM Compound: Bz	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 28557430]
MCF7	IC₅₀	18.37 μM Compound: Bortezomib	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29426629]
MDA-MB-231	GI₅₀	1.26 nM Compound: Bortezomib, Velcade	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 24946214]
MDA-MB-231	IC₅₀	16.65 nM Compound: PS-341	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27769033]
MDA-MB-231	IC₅₀	6.5 nM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28182990]
MDA-MB-231	IC₅₀	0.017 μM Compound: Bortezomib	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28634039]
MDA-MB-231	IC₅₀	3.125 μM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 29426629]
MDA-MB-231	IC₅₀	0.003 μM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.46 μM Compound: Bortezomib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
MDA-MB-435	GI₅₀	0.44 nM Compound: Bortezomib, Velcade	Growth inhibition of human MDA-MB-435 cells Growth inhibition of human MDA-MB-435 cells	[PMID: 24946214]
MDA-MB-468	GI₅₀	1.48 nM Compound: Bortezomib, Velcade	Growth inhibition of human MDA-MB-468 cells Growth inhibition of human MDA-MB-468 cells	[PMID: 24946214]
MGC-803	IC₅₀	5.782 nM Compound: PS-341	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 27769033]
MGC-803	IC₅₀	0.008 μM Compound: Bortezomib	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 28634039]
MKN-45	IC₅₀	7.15 nM Compound: PS-341	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 27769033]
MM1.S	IC₅₀	2.5 nM Compound: BTZ	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
MM1.S	IC₅₀	0.0026 μM Compound: Bortezomib	Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay	[PMID: 34969245]
MM1.S	IC₅₀	0.0032 μM Compound: Bortezomib	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay	[PMID: 36512676]
MM1.S	EC₅₀	0.002 μM Compound: BTZ	Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay	[PMID: 36608337]
MOLT-4	EC₅₀	21 nM Compound: 1, bortezomib	Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells	[PMID: 18247547]
MOLT-4	EC₅₀	21 nM Compound: 8	Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate	[PMID: 22503349]
MOLT-4	GI₅₀	0.51 nM Compound: Bortezomib, Velcade	Growth inhibition of human MOLT4 cells Growth inhibition of human MOLT4 cells	[PMID: 24946214]
Multiple myeloma cancer stem cell	IC₅₀	8.4 nM Compound: BTZ	Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay	[PMID: 30108696]
NCI/ADR-RES	GI₅₀	12.3 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-ADR-RES cells Growth inhibition of human NCI-ADR-RES cells	[PMID: 24946214]
NCI-H226	GI₅₀	0.46 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H226 cells Growth inhibition of human NCI-H226 cells	[PMID: 24946214]
NCI-H23	GI₅₀	1 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H23 cells Growth inhibition of human NCI-H23 cells	[PMID: 24946214]
NCI-H23	IC₅₀	0.01 μM Compound: Btz	Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H322M	GI₅₀	17.8 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H322M cells Growth inhibition of human NCI-H322M cells	[PMID: 24946214]
NCI-H460	IC₅₀	115 nM Compound: bortezomib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 19537716]
NCI-H460	IC₅₀	780 nM Compound: bortezomib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 20158184]
NCI-H460	GI₅₀	4.47 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H460 cells Growth inhibition of human NCI-H460 cells	[PMID: 24946214]
NCI-H522	GI₅₀	1.44 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H522 cells Growth inhibition of human NCI-H522 cells	[PMID: 24946214]
NCI-H727	IC₅₀	0.025 μM Compound: Btz	Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H929	IC₅₀	10.85 nM Compound: Bortezomib	Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay	[PMID: 24767818]
OVCAR-3	GI₅₀	0.54 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR3 cells Growth inhibition of human OVCAR3 cells	[PMID: 24946214]
OVCAR-4	GI₅₀	1.95 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR4 cells Growth inhibition of human OVCAR4 cells	[PMID: 24946214]
OVCAR-5	GI₅₀	1.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR5 cells Growth inhibition of human OVCAR5 cells	[PMID: 24946214]
OVCAR-8	GI₅₀	2.63 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR8 cells Growth inhibition of human OVCAR8 cells	[PMID: 24946214]
PBMC	IC₅₀	<35 nM Compound: Bortezomib	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
PBMC	IC₅₀	2.7 nM Compound: 1	Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay	[PMID: 31283222]
PC-3	IC₅₀	7 nM Compound: bortezomib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20158184]
PC-3	IC₅₀	8.3 nM Compound: bortezomib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21077681]
PC-3	GI₅₀	2.63 nM Compound: Bortezomib, Velcade	Growth inhibition of human PC3 cells Growth inhibition of human PC3 cells	[PMID: 24946214]
PC-3	GI₅₀	0.04 μM Compound: Bortezomib	Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
RAW264.7	IC₅₀	0.03 μM Compound: Bortezomib	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay	[PMID: 32738985]
RKO	IC₅₀	20.8 nM Compound: Bortezomib	Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
RPMI-8226	IC₅₀	0.0088 μM Compound: 3	Cytotoxicity against human RPMI8226 cells Cytotoxicity against human RPMI8226 cells	[PMID: 20727746]
RPMI-8226	IC₅₀	9.5 nM Compound: PS-341, Bortezomib	Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay	[PMID: 24119559]
RPMI-8226	IC₅₀	7.96 nM Compound: Bortezomib	Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 24767818]
RPMI-8226	GI₅₀	0.23 nM Compound: Bortezomib, Velcade	Growth inhibition of human RPMI8226 cells Growth inhibition of human RPMI8226 cells	[PMID: 24946214]
RPMI-8226	IC₅₀	3.88 nM Compound: Bortezomib	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 26965867]
RPMI-8226	IC₅₀	6.7 nM Compound: Bortezomib	Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay	[PMID: 28182990]
RPMI-8226	IC₅₀	11.2 nM Compound: Bortezomib	Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
RPMI-8226	IC₅₀	1.43 nM Compound: PS-341	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
RPMI-8226	IC₅₀	0.0064 μM Compound: BTZ	Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay	[PMID: 34445874]
RPMI-8226	IC₅₀	4.7 nM Compound: BTZ	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
RPMI-8226	IC₅₀	0.0045 μM Compound: Bortezomib	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay	[PMID: 34969245]
RPMI-8226	IC₅₀	0.0056 μM Compound: Bortezomib	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay	[PMID: 36512676]
RPMI-8226	EC₅₀	0.004 μM Compound: BTZ	Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay	[PMID: 36608337]
RPMI-8226	IC₅₀	5.24 μM Compound: Bortezomib	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
RPMI-8226	IC₅₀	80 nM Compound: Bortezomib	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay	[PMID: 38381886]
RXF 393	GI₅₀	0.71 nM Compound: Bortezomib, Velcade	Growth inhibition of human RXF393 cells Growth inhibition of human RXF393 cells	[PMID: 24946214]
SF-268	GI₅₀	1.17 nM Compound: Bortezomib, Velcade	Growth inhibition of human SF268 cells Growth inhibition of human SF268 cells	[PMID: 24946214]
SF-295	GI₅₀	1.7 nM Compound: Bortezomib, Velcade	Growth inhibition of human SF295 cells Growth inhibition of human SF295 cells	[PMID: 24946214]
SF-539	GI₅₀	0.59 nM Compound: Bortezomib, Velcade	Growth inhibition of human SF539 cells Growth inhibition of human SF539 cells	[PMID: 24946214]
SK-MEL-2	GI₅₀	1.07 nM Compound: Bortezomib, Velcade	Growth inhibition of human SK-MEL-2 cells Growth inhibition of human SK-MEL-2 cells	[PMID: 24946214]
SK-MEL-28	GI₅₀	0.46 nM Compound: Bortezomib, Velcade	Growth inhibition of human SK-MEL-28 cells Growth inhibition of human SK-MEL-28 cells	[PMID: 24946214]
SK-MEL-5	GI₅₀	0.68 nM Compound: Bortezomib, Velcade	Growth inhibition of human SK-MEL-5 cells Growth inhibition of human SK-MEL-5 cells	[PMID: 24946214]
SK-OV-3	IC₅₀	130 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 19537716]
SK-OV-3	IC₅₀	151 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 20158184]
SK-OV-3	IC₅₀	66.8 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 21077681]
SK-OV-3	GI₅₀	13.8 nM Compound: Bortezomib, Velcade	Growth inhibition of human SKOV3 cells Growth inhibition of human SKOV3 cells	[PMID: 24946214]
SK-OV-3	IC₅₀	1.62 nM Compound: PS-341	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 27769033]
SK-OV-3	IC₅₀	12.9 nM Compound: Bortezomib	Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay	[PMID: 29767973]
SN12C	GI₅₀	1.1 nM Compound: Bortezomib, Velcade	Growth inhibition of human SN12C cells Growth inhibition of human SN12C cells	[PMID: 24946214]
SNB-19	GI₅₀	2.04 nM Compound: Bortezomib, Velcade	Growth inhibition of human SNB19 cells Growth inhibition of human SNB19 cells	[PMID: 24946214]
SNB-75	GI₅₀	2.04 nM Compound: Bortezomib, Velcade	Growth inhibition of human SNB75 cells Growth inhibition of human SNB75 cells	[PMID: 24946214]
SR	GI₅₀	0.85 nM Compound: Bortezomib, Velcade	Growth inhibition of human SR cells Growth inhibition of human SR cells	[PMID: 24946214]
SW1990	IC₅₀	79.06 nM Compound: PS-341	Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 27769033]
SW480	IC₅₀	50 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19537716]
SW480	IC₅₀	6.1 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 20158184]
SW480	IC₅₀	12.3 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 21077681]
SW-620	GI₅₀	0.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human SW620 cells Growth inhibition of human SW620 cells	[PMID: 24946214]
T47D	GI₅₀	0.6 nM Compound: Bortezomib, Velcade	Growth inhibition of human T47D cells Growth inhibition of human T47D cells	[PMID: 24946214]
THP-1	IC₅₀	6.28 nM Compound: BTZ	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
TK-10	GI₅₀	1 nM Compound: Bortezomib, Velcade	Growth inhibition of human TK10 cells Growth inhibition of human TK10 cells	[PMID: 24946214]
TOV21G	IC₅₀	16.7 nM Compound: Bortezomib	Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
U-251	GI₅₀	1.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human U251 cells Growth inhibition of human U251 cells	[PMID: 24946214]
U-266	IC₅₀	2.45 nM Compound: bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 19537716]
U-266	IC₅₀	12.2 nM Compound: Bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 19747832]
U-266	IC₅₀	8.8 nM Compound: bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 20158184]
U-266	IC₅₀	5.73 nM Compound: Bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTS assay Cytotoxicity against human U266 cells after 72 hrs by MTS assay	[PMID: 26965867]
U-266	GI₅₀	0.001 μM Compound: Bortezomib	Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
U-266	IC₅₀	11.63 nM Compound: Bortezomib	Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
U-266	IC₅₀	12.5 nM Compound: PS-341	Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
U-87MG ATCC	IC₅₀	7.86 μM Compound: Bortezomib	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
UACC-257	GI₅₀	0.59 nM Compound: Bortezomib, Velcade	Growth inhibition of human UACC257 cells Growth inhibition of human UACC257 cells	[PMID: 24946214]
UACC-62	GI₅₀	0.91 nM Compound: Bortezomib, Velcade	Growth inhibition of human UACC62 cells Growth inhibition of human UACC62 cells	[PMID: 24946214]
UO-31	GI₅₀	1.05 nM Compound: Bortezomib, Velcade	Growth inhibition of human UO31 cells Growth inhibition of human UO31 cells	[PMID: 24946214]
WM 266-4	IC₅₀	0.035 μM Compound: Bortezomib, Velcade, PS-341	Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay	[PMID: 22206869]

In Vitro

Bortezomib (PS-341) (100 nM; 8 hours) results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1^[1].
Bortezomib (PS-341) (5-100 nM; 20 hours) induces apoptosis in mantle-cell lymphoma (MCL) cell lines^[3].
Bortezomib (PS-341) (20 nM; 1-14 hours) induces Noxa up-regulation in both MCL cell lines^[3].
The IC₅₀ of Bortezomib (PS-341) is found to be 2.46 nM for 26S proteasome in the B16F10 cells^[4].
Bortezomib (PS-341) suppresses several anti-apoptotic proteins (e.g., Bcl-XL, Bcl-2, and STAT-3)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

PC-3 cells
Concentration:

100 nM
Incubation Time:

8 hours
Result:

Resulted in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1.

Apoptosis Analysis^[3]

Cell Line:

JVM-2, Granta-519, Jeko, REC-1 cells (MCL cell lines)
Concentration:

5-100 nM
Incubation Time:

20 hours
Result:

The median LD50 for these MCL cell lines was 31 nM (range, 18.2-60.1 nM).

Western Blot Analysis^[3]

Cell Line:

wtp53 (Granta-519), mutp53 (Jeko) cells
Concentration:

20 nM
Incubation Time:

1, 2, 4, 6, 14 hours
Result:

Noxa up-regulation was detected between 2 to 4 hours after bortezomib (PS-341).

In Vivo

Bortezomib (PS-341) (0.3-1 mg/kg; i.v.; once weekly for 4 weeks) inhibits PC-3 Tumor Growth in Nude Mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male nude mice (xenograft tumor model bearing PC-3 cells)^[1]
Dosage:

0.3, 1 mg/kg
Administration:

Intravenous injection; once weekly for 4 weeks
Result:

Resulted in a significant decrease in tumor growth ~60% at dose of 1 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 179324-69-7
Appearance Solid
Molecular Weight 384.24
Formel C₁₉H₂₅BN₄O₄
Color White to off-white
SMILES

OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
Synonyms

PS-341; LDP-341; NSC 681239
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (261)

All IFWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Glucosidase alpha neutral C promotes influenza virus replication by inhibiting proteosome-dependent degradation of hemagglutinin. [Abstract]

2025 Apr 23;10(1):131. PMID: 40263249
Nature

Lymph node environment drives FSP1 targetability in metastasizing melanoma. [Abstract]

2026 Jan;649(8096):477-486. PMID: 41193799
Cell

BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. [Abstract]

2019 Jul 11;178(2):330-345.e22. PMID: 31257027
Cancer Discov

Divergent Evolution of Malignant Subclones Maintains a Balance Between Induced Aggressiveness and Intrinsic Drug Resistance in T Cell Cancer. [Abstract]

2025 Jun 16. PMID: 40516109
Nat Cancer

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. [Abstract]

2020 Feb;1(2):235-248. PMID: 32613204
Nat Immunol

An epithelial cell-derived metabolite tunes immunoglobulin A secretion by gut-resident plasma cells. [Abstract]

2023 Mar;24(3):531-544. PMID: 36658240
Cell Res

Asymmetric division in a two-cell-like state rejuvenates embryonic stem cells. [Abstract]

2026 Mar;36(3):219-232. PMID: 41634384
Cancer Commun (Lond)

Orchestrated desaturation reprogramming from stearoyl-CoA desaturase to fatty acid desaturase 2 in cancer epithelial-mesenchymal transition and metastasis. [Abstract]

2025 Mar;45(3):245-280. PMID: 39722173
Drug Resist Updat

NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1. [Abstract]

2024 Mar:73:101040. PMID: 38228036
Nat Commun

Tunable gene control via RNA splicing with a clinically approved small molecule. [Abstract]

2026 May 30. PMID: 42218123
Nat Commun

Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation. [Abstract]

2025 Sep 1;16(1):8155. PMID: 40890111
Nat Commun

Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition. [Abstract]

2025 Aug 21;16(1):7689. PMID: 40841360
Nat Commun

A mouse protozoan boosts antigen-specific mucosal IgA responses in a specific lipid metabolism- and signaling-dependent manner. [Abstract]

2024 Sep 10;15(1):7914. PMID: 39256385
Nat Commun

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma. [Abstract]

2024 Aug 9;15(1):6810. PMID: 39122682
Nat Commun

FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma. [Abstract]

2024 Jun 5;15(1):4790. PMID: 38839752
Nat Commun

BioE3 identifies specific substrates of ubiquitin E3 ligases. [Abstract]

2023 Nov 23;14(1):7656. PMID: 37996419
Nat Commun

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. [Abstract]

2022 Oct 2;13(1):5789. PMID: 36184661
Nat Commun

The ubiquitylation of IL-1β limits its cleavage by caspase-1 and targets it for proteasomal degradation. [Abstract]

2021 May 11;12(1):2713. PMID: 33976225
Nat Commun

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]

2020 Sep 4;11(1):4417. PMID: 32887884
Nat Commun

pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. [Abstract]

2017 May 22;8:15398. PMID: 28530236
Cell Death Differ

TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11/xCT K11-linked ubiquitination and degradation. [Abstract]

2024 Jan;31(1):53-64. PMID: 37978273
Acta Pharm Sin B

Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy. [Abstract]

2024 Dec;14(12):5382-5392. PMID: 39807332
Acta Pharm Sin B

Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis. [Abstract]

2024 Aug;14(8):3493-3512. PMID: 39220878
Acta Pharm Sin B

Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR. [Abstract]

2022 Mar;12(3):1339-1350. PMID: 35530159
Hemasphere

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. [Abstract]

2021 Jun 12;5(7):e602. PMID: 34136753
Adv Sci (Weinh)

2026 Apr 9.
Adv Sci (Weinh)

Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. [Abstract]

2026 Apr;13(21):e18975. PMID: 41655233
Adv Sci (Weinh)

TRIM47 Regulates Energy Metabolism via Glycolytic Reprogramming to Drive Hepatocellular Carcinoma Progression and Represents an Efficient Therapeutic Target. [Abstract]

2026 Mar;13(17):e16996. PMID: 41632101
Adv Sci (Weinh)

OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα. [Abstract]

2026 Jan 20:e16355. PMID: 41560298
Adv Sci (Weinh)

NADH-Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis. [Abstract]

2025 Dec 5:e20444. PMID: 41346305
Adv Sci (Weinh)

The Crosstalk Between CRL5 and APC/C E3 Ligases Regulates Metastasis and Chemosensitivity of Cancer Cells. [Abstract]

2025 Oct 29:e12652. PMID: 41159544
Adv Sci (Weinh)

Palmitoyltransferase ZDHHC3 Aggravates Nonalcoholic Steatohepatitis by Targeting S-Palmitoylated IRHOM2. [Abstract]

2023 Oct;10(28):e2302130. PMID: 37544908
Leukemia

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities. [Abstract]

2023 Apr;37(4):843-853. PMID: 36813992
Theranostics

ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. [Abstract]

2019 Aug 14;9(21):6334-6353. PMID: 31534554
Chem Eng J

2026 Mar 12.
J Exp Clin Cancer Res

OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway. [Abstract]

2024 Dec 26;43(1):330. PMID: 39721999
Cell Discov

Suppressing protein damage response to overcome multidrug resistance in cancer therapy. [Abstract]

2025 Sep 30;11(1):80. PMID: 41027888
Plant Commun

Phosphorylation of PIP2;7 by CPK28 or Phytophthora kinase effectors dampens pattern-triggered immunity in Arabidopsis. [Abstract]

2024 Sep 13:101135. PMID: 39277790
J Control Release

Immunogenic cell death-primed autophagosome vaccines drive dendritic cell cross-presentation and suppress colon cancer metastasis. [Abstract]

2026 May 10:393:114827. PMID: 41856327
J Hazard Mater

Di-(2-ethylhexyl) phthalate (DEHP) and its metabolite promote multiple myeloma progression and bortezomib resistance. [Abstract]

2025 Sep 5:495:139147. PMID: 40633344
J Hazard Mater

Copper mediated follicular atresia: Implications for granulosa cell death. [Abstract]

2024 Jul 31:477:135391. PMID: 39106724
Gut Microbes

IgA-mediated control of host-microbial interaction during weaning reaction influences gut inflammation. [Abstract]

2024 Jan-Dec;16(1):2323220. PMID: 38439579
EBioMedicine

VIPAS39 confers ferroptosis resistance in epithelial ovarian cancer through exporting ACSL4. [Abstract]

2025 Apr:114:105646. PMID: 40088627
J Immunother Cancer

HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion. [Abstract]

2025 Nov 28;13(11):e011976. PMID: 41314980
Cell Rep Med

Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. [Abstract]

2025 Jul 15;6(7):102211. PMID: 40609539
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Clin Cancer Res

A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. [Abstract]

2019 Jun 15;25(12):3630-3642. PMID: 30796032

Bortezomib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jun 15;25(12):3630-3642. [Abstract]

H1975 cells treated with 5 μmol/L MTI-31 alone or in combination with 10 μmol/L CQ or 0.01 μmol/L PS-341.
Nat Struct Mol Biol

PEX14 condensates recruit receptor and cargo pairs for peroxisomal protein import. [Abstract]

2025 Jun 24. PMID: 40555785
Cancer Lett

DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer. [Abstract]

2023 Aug 1:568:216288. PMID: 37390887
Cancer Lett

LncRNA MNX1-AS1 sustains inactivation of Hippo pathway through a positive feedback loop with USP16/IGF2BP3 axis in gallbladder cancer. [Abstract]

2022 Oct 28:547:215862. PMID: 35953000
Cancer Lett

All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase. [Abstract]

2020 Mar 31;473:130-138. PMID: 31904486
Cell Death Dis

Targeting PPARγ via SIAH1/2-mediated ubiquitin-proteasomal degradation as a new therapeutic approach in luminal-type bladder cancer. [Abstract]

2024 Dec 18;15(12):908. PMID: 39695138
Cell Death Dis

PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6. [Abstract]

2023 Aug 9;14(8):512. PMID: 37558663
Cell Death Dis

Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response. [Abstract]

2023 Aug 26;14(8):561. PMID: 37626037
Cell Death Dis

PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNFα-mediated cell death. [Abstract]

2022 Sep 7;13(9):773. PMID: 36071040
Cell Death Dis

ΔNp63α promotes Bortezomib resistance via the CYGB-ROS axis in head and neck squamous cell carcinoma. [Abstract]

2022 Apr 9;13(4):327. PMID: 35397613
Cell Death Dis

UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. [Abstract]

2022 May 12;13(5):451. PMID: 35551175
Cell Death Dis

ALCAM regulates multiple myeloma chemoresistant side population. [Abstract]

2022 Feb 10;13(2):136. PMID: 35145058
Cell Death Dis

TRIB2 modulates proteasome function to reduce ubiquitin stability and protect liver cancer cells against oxidative stress. [Abstract]

2021 Jan 7;12(1):42. PMID: 33414446
Cell Death Dis

The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses. [Abstract]

2018 May 22;9(6):604. PMID: 29789637

Bortezomib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]

The accumulated SQSTM1 by either proteasome inhibitors or PPI was sensitive to autophagy mediated degradation. AGS cells were pretreated with 25 and 50nM bortezomib for 1h, and then incubated with 500nM torin 1 for 24h (g). After pretreatment with PPI for 24h in pH 7.4 or pH 6.5 condition, rapamycin (1μM) or torin 1 (500 nM) was added for another 24h (h). The protein level of SQSTM1 was measured by western blot analysis (g, h).

Bortezomib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]

Different concentrations of two classical proteasome inhibitors Bortezomib and MG132 are added. AGS cells are either untreated or treated with Bortezomib (25 nM) or MG132 (0.1 μM) for 24 h in the absence or presence of baf A1 (100 nM).
Proc Natl Acad Sci U S A

Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT). [Abstract]

2023 Jan 31;120(5):e2213777120. PMID: 36693106
Proc Natl Acad Sci U S A

HOIP modulates the stability of GPx4 by linear ubiquitination. [Abstract]

2022 Nov;119(44):e2214227119. PMID: 36279464
Cell Commun Signal

MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy. [Abstract]

2025 Jul 18;23(1):346. PMID: 40682103
Cell Commun Signal

Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML. [Abstract]

2025 Jan 28;23(1):53. PMID: 39875995
Dev Cell

Lactylation of LSD1 is an acquired epigenetic vulnerability of BRAFi/MEKi-resistant melanoma. [Abstract]

2025 Mar 20:S1534-5807(25)00121-2. PMID: 40132584
Int J Biol Macromol

Identification of c.146G > A mutation in a Fabry patient and its correction by customized Cas9 base editors in vitro. [Abstract]

2024 Oct 25:136922. PMID: 39490876
Acta Pharmacol Sin

Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma. [Abstract]

2025 Mar 25. PMID: 40133626
Acta Pharmacol Sin

Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway. [Abstract]

2025 Jul;46(7):2041-2055. PMID: 39984622
Acta Pharmacol Sin

Integrating yeast chemical genomics and mammalian cell pathway analysis. [Abstract]

2019 Sep;40(9):1245-1255. PMID: 31138898
EMBO J

Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers. [Abstract]

2025 Nov 3. PMID: 41184587
Phytomedicine

Columbianadin targets TRIM7 to maintain P2X7 palmitoylation, inhibiting cuproptosis in synovial M2 macrophages. [Abstract]

2025 Oct:146:157091. PMID: 40768810
EMBO J

Interferon-induced PARP14-mediated ADP-ribosylation in p62 bodies requires the ubiquitin-proteasome system. [Abstract]

2025 Apr 7. PMID: 40195501
EMBO J

E3 ubiquitin ligase CHIP facilitates cAMP and cGMP signalling cross-talk by polyubiquitinating PDE9A. [Abstract]

2025 Feb;44(4):1249-1273. PMID: 39806097
Phytomedicine

Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis. [Abstract]

2024 Jun:128:155401. PMID: 38507850
Phytomedicine

Sculponeatin A promotes the ETS1-SYVN1 interaction to induce SLC7A11/xCT-dependent ferroptosis in breast cancer. [Abstract]

2023 Aug:117:154921. PMID: 37327642
Free Radic Biol Med

Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma. [Abstract]

2023 Jul:203:86-101. PMID: 37044150
Chemosphere

Bisphenol C induces developmental defects in liver and intestine through mTOR signaling in zebrafish (Danio rerio). [Abstract]

2023 May:322:138195. PMID: 36822516
New Phytol

An F-box protein attenuates fungal xylanase-triggered immunity by destabilizing LRR-RLP NbEIX2 in a SOBIR1-dependent manner. [Abstract]

2022 Dec;236(6):2202-2215. PMID: 36151918
NPJ Precis Oncol

Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]

2025 Nov 21;9(1):373. PMID: 41272086
Clin Sci

LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension. [Abstract]

2025 May 7:CS20255922. PMID: 40332105
Br J Pharmacol

Sculponeatin A induces mitochondrial dysfunction in non-small cell lung cancer through WWP2-mediated degradation of mitochondrial STAT3. [Abstract]

2025 Jun;182(12):2662-2681. PMID: 39993792
Br J Pharmacol

A novel sorbicillinoid compound as a potent anti-inflammation agent through inducing NLRP3 protein degradation. [Abstract]

2023 Aug;180(15):1930-1948. PMID: 36788033
NPJ Breast Cancer

Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets. [Abstract]

2023 Dec 2;9(1):97. PMID: 38042915
J Transl Med

CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK/STAT3/PIM1 axis. [Abstract]

2025 Nov 17;23(1):1292. PMID: 41250171
J Transl Med

Single-cell transcriptomics identifies PDIA4 as a marker of progression and therapeutic vulnerability in multiple myeloma. [Abstract]

2025 Oct 21;23(1):1136. PMID: 41121130
J Transl Med

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]

2024 Dec 3;22(1):1095. PMID: 39623468
Curr Biol

UBP12 and UBP13 deubiquitinases destabilize the CRY2 blue light receptor to regulate Arabidopsis growth. [Abstract]

2022 Aug 8;32(15):3221-3231.e6. PMID: 35700731
Amyloid

Cell assay for the identification of amyloid inhibitors in systemic AA amyloidosis. [Abstract]

2019 Mar;26(1):24-33. PMID: 30739503
Oncogene

Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2. [Abstract]

2021 Nov;40(44):6273-6283. PMID: 34556812
Cell Chem Biol

Exploring the target scope of KEAP1 E3 ligase-based PROTACs. [Abstract]

2022 Oct 20;29(10):1470-1481.e31. PMID: 36070758
Blood Adv

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. [Abstract]

2025 Jul 2:bloodadvances.2024015322. PMID: 40601898
Cell Death Discov

ChaC1-based drug screenings identify a synergistic lethal effect of auranofin and proteasome inhibitors in hepatocellular carcinoma cells. [Abstract]

2025 Nov 17;11(1):532. PMID: 41249117
Cell Death Discov

YAP ISGylation increases its stability and promotes its positive regulation on PPP by stimulating 6PGL transcription. [Abstract]

2022 Feb 11;8(1):59. PMID: 35149670
Cell Rep

The Hippo pathway kinase MST1 mediates a feedback loop to maintain NLRP3 inflammasome homeostasis. [Abstract]

2025 Jul 26;44(8):116076. PMID: 40716062
Cell Rep

The N-degron pathway mediates the autophagic degradation of cytosolic mitochondrial DNA during sterile innate immune responses. [Abstract]

2024 Dec 21;44(1):115094. PMID: 39709605
Cell Rep

Deciphering ER stress-unfolded protein response relationship by visualizing unfolded proteins in the ER. [Abstract]

2024 Jun 11;43(6):114358. PMID: 38865243
Cell Rep

The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells. [Abstract]

2022 Sep 27;40(13):111428. PMID: 36170818
Cell Rep

The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote Reprogramming. [Abstract]

2020 Jul 14;32(2):107877. PMID: 32668244
J Med Chem

Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. [Abstract]

2026 Jan 22;69(2):1119-1134. PMID: 41482966
J Med Chem

α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity. [Abstract]

2025 Dec 25;68(24):26405-26417. PMID: 41344819
J Med Chem

Discovery and Mechanistic Study of Novel Mycobacterium tuberculosis ClpP1P2 Inhibitors. [Abstract]

2023 Dec 28;66(24):16597-16614. PMID: 38088921
Sci Signal

Degradation of HDAC10 by autophagy promotes IRF3-mediated antiviral innate immune responses. [Abstract]

2022 Dec 20;15(765):eabo4356. PMID: 36538592
J Cell Biol

Differential impacts of ribosomal protein haploinsufficiency on mitochondrial function. [Abstract]

2025 Mar 3;224(3):e202404084. PMID: 39786340
Elife

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. [Abstract]

2018 Aug 1;7:e38430. PMID: 30067223

Bortezomib purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]

Kelly cells are treated with increasing concentrations of Thalidomide and co-treated with 5 μM Bortezomib, 5 μM MLN4924, 0.5 μM MLN7243, or DMSO as a control. Following 24 h incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.
J Agric Food Chem

Isolation, Identification, and Immunomodulatory Mechanism of Peptides from Lepidium meyenii (Maca) Protein Hydrolysate. [Abstract]

2022 Apr 13;70(14):4328-4341. PMID: 35357828
J Agric Food Chem

Alpinia hainanensis Rhizome Extract Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis: Active Ingredient Investigation and Evaluation. [Abstract]

2022 Apr 6;70(13):3989-3999. PMID: 35321548
Ecotoxicol Environ Saf

Phthalates promote lenvatinib resistance in hepatocellular carcinoma through the HPX-MAPK pathway. [Abstract]

2025 Aug 25:303:118932. PMID: 40858030
JCI Insight

Neutrophil extracellular traps contribute to coagulopathy after traumatic brain injury. [Abstract]

2023 Mar 22;8(6):e141110. PMID: 36802340
Eur J Med Chem

A low toxic CRM1 degrader: Synthesis and anti-proliferation on MGC803 and HGC27. [Abstract]

2020 Nov 15;206:112708. PMID: 32810752
Neurosci Bull

A Non-spinal Neural Circuit for Transmitting Information of Bladder Conditions. [Abstract]

2025 Dec 27. PMID: 41455075
Int J Mol Med

Proteasome inhibitors decrease paclitaxel‑induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1/cyclin B1. [Abstract]

2021 Oct;48(4):193. PMID: 34435645
Biomater Sci

Versatile functionalization of surface-tailorable polymer nanohydrogels for drug delivery systems. [Abstract]

2018 Dec 18;7(1):247-261. PMID: 30465554
Biochem Pharmacol

Apelin-13 improves pulmonary epithelial barrier function in a mouse model of LPS-induced acute lung injury by inhibiting Chk1-mediated DNA damage. [Abstract]

2024 May 25:116297. PMID: 38801925
Biochem Pharmacol

IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro. [Abstract]

2022 Oct:204:115232. PMID: 36030831
Mol Cancer Ther

Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]

2026 Jun 13. PMID: 42295240
World J Gastroenterol

Wogonin derivative V8 enhances bortezomib efficacy in gastric carcinoma by disrupting lysosome-mediated drug resistance. [Abstract]

2026 Feb 28;32(8):113299. PMID: 41809875
Mol Ther Oncol

The oligosaccharyltransferase complex is an essential component of multiple myeloma plasma cells. [Abstract]

2025 Mar 8;33(2):200964. PMID: 40200920
Cells

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma. [Abstract]

2026 May 1;15(9):831. PMID: 42121932
Cells

Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads. [Abstract]

2021 Dec 6;10(12):3431. PMID: 34943940
Life Sci

Melatonin ameliorates myocardial ischemia/reperfusion injury via regulating the ubiquitin-proteasome system. [Abstract]

2025 Nov 1:380:123973. PMID: 40962023
Commun Biol

Infection with novel duck reovirus induces stress granule and methylation-mediated host translational shutoff in Muscovy ducklings. [Abstract]

2024 Nov 21;7(1):1549. PMID: 39572728
Commun Biol

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements. [Abstract]

2022 Nov 26;5(1):1295. PMID: 36435843
Stem Cell Reports

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. [Abstract]

2017 Dec 12;9(6):1948-1960. PMID: 29198824
Respir Res

SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway. [Abstract]

2024 Oct 5;25(1):362. PMID: 39369217
Mol Plant Pathol

Phytoplasma effector SWP1 induces witches' broom symptom by destabilizing the TCP transcription factor BRANCHED1. [Abstract]

2018 Dec;19(12):2623-2634. PMID: 30047227
Pharmaceuticals (Basel)

The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells. [Abstract]

2024 Aug 20;17(8):1089. PMID: 39204194
Cell Oncol (Dordr)

Proteasomal deubiquitylase activity enhances cell surface recycling of the epidermal growth factor receptor in non-small cell lung cancer. [Abstract]

2022 Oct;45(5):951-965. PMID: 36129611
Int J Cancer

Beneficial effects of aerobic exercises on multiple myeloma: Mechanisms and clinical observations. [Abstract]

2025 Jul 4. PMID: 40613758
Int Immunopharmacol

Different roles of bortezomib and ONX 0914 in acute kidney injury. [Abstract]

2020 Mar 3;82:106259. PMID: 32143000
Eur J Pharmacol

Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells. [Abstract]

2017 Nov 15:815:147-155. PMID: 28887042

Bortezomib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2017 Nov 15:815:147-155. [Abstract]

Shown are GFPu fluorescent images of the GFPu-HEK293 cells treated with CuSO₄ (Cu, 20 μM), HK (20 μM), HK-Cu (HC, 20 μM), or Velcade (Vel, 100 nM).
J Med Virol

E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting proteasome-dependent degradation of NSP5. [Abstract]

2024 Sep;96(9):e29891. PMID: 39223933
Antimicrob Agents Chemother

Inhibitors of the 20S proteasome β5 subunit as potent and selective agents against Trichomonas vaginalis. [Abstract]

2025 Dec 10;69(12):e0089325. PMID: 41218108
Mol Pharm

Using Metal-Organic Framework Nanoparticles for Targeted Codelivery of Bortezomib and Iron Ions to Mitochondrial TOM20 to Induce Ferroptosis for Colorectal Cancer Treatment. [Abstract]

2025 Aug 4;22(8):4865-4878. PMID: 40671590
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Front Cell Dev Biol

SYVN1-MTR4-MAT2A Signaling Axis Regulates Methionine Metabolism in Glioma Cells. [Abstract]

2021 Mar 30:9:633259. PMID: 33859984
Biochim Biophys Acta Mol Basis Dis

The deubiquitinase OTUB1 governs lung cancer cell fitness by modulating proteostasis of OXPHOS proteins. [Abstract]

2023 Oct;1869(7):166767. PMID: 37245529
FASEB J

Cullin 2-RBX1 E3 ligase and USP2 regulate antithrombin ubiquitination and stability. [Abstract]

2021 Aug;35(8):e21800. PMID: 34324733
J Cell Mol Med

Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia. [Abstract]

2021 Mar;25(6):3124-3135. PMID: 33599085
iScience

An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma. [Abstract]

2026 Feb 28;29(4):115174. PMID: 41858619
iScience

TLR9 decreases FOXO3 expression to prevent excessive inflammation in macrophage activation syndrome. [Abstract]

2025 Nov 17;28(12):114098. PMID: 41438053
iScience

Computational design of diverse nuclear factor erythroid 2 activators with cellular antioxidative activity. [Abstract]

2025 May 8;28(6):112621. PMID: 40502689
iScience

Dynamic regulation of P-TEFb by 7SK snRNP is integral to the DNA damage response to regulate chemotherapy sensitivity. [Abstract]

2022 Aug 4;25(9):104844. PMID: 36034227
iScience

Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing. [Abstract]

2022 Jul 19;25(8):104781. PMID: 35992084
J Inflamm Res

Aqueous Extract of Cimicifuga dahurica Reprogramming Macrophage Polarization by Activating TLR4-NF-κB Signaling Pathway. [Abstract]

2022 Feb 15;15:1027-1046. PMID: 35210810
Transl Oncol

poly(I:C) synergizes with proteasome inhibitors to induce apoptosis in cervical cancer cells. [Abstract]

2022 Apr;18:101362. PMID: 35151092
J Cell Physiol

Compensatory reactions of B cells in response to chronic HIV-1 Tat exposure. [Abstract]

2025 Jan;240(1):e31459. PMID: 39373061
Virol Sin

Proteasome Inhibitor PS-341 Effectively Blocks Infection by the Severe Fever with Thrombocytopenia Syndrome Virus. [Abstract]

2019 Oct;34(5):572-582. PMID: 31637631
J Biol Chem

Andrographolide targets syndecan4 to impair its interaction with syntenin and inhibits the biogenesis of small extracellular vesicles. [Abstract]

2026 Jan 20:111182. PMID: 41570990
Sci Rep

NPS-2143 suppresses malignant phenotypes of retinoblastoma cells involved in regulating NF-κB pathway. [Abstract]

2025 May 9;15(1):16209. PMID: 40346093
Sci Rep

Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses. [Abstract]

2022 Nov 5;12(1):18811. PMID: 36335206
Aging

Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer. [Abstract]

2020 Nov 25;12(24):25730-25743. PMID: 33234722
J Virol

SUMOylation-dependent degradation of nucleocapsid is responsible for Pestivirus uncoating. [Abstract]

2025 Nov 25:e0164825. PMID: 41288382
Chem Res Toxicol

The Selective SIRT3 Inhibitor 3-TYP Represses Primary Myeloma Growth by Reducing c-Myc Stability. [Abstract]

2024 Jun 17;37(6):1062-1069. PMID: 38815162
J Virol

ATF6-Mediated Unfolded Protein Response Facilitates Adeno-associated Virus 2 (AAV2) Transduction by Releasing the Suppression of the AAV Receptor on Endoplasmic Reticulum Stress. [Abstract]

2022 Feb 9;96(3):e0110321. PMID: 34851146
Cell Signal

PERK-eIF2alpha-mediated translational inhibition of MCL-1 contributes to potential 2-deoxy-D-glucose and BAD mimetic combinatorial cancer therapy. [Abstract]

2025 Dec 19:139:112333. PMID: 41423011
J Photochem Photobiol B

Suppression of NRF2 by photodynamic action to enhance bortezomib-triggered DNA damage for synergistic colorectal cancer therapy. [Abstract]

2025 Apr 3:267:113162. PMID: 40199069
Cell Signal

Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity. [Abstract]

2025 Mar 25:111767. PMID: 40147548
Cell Signal

tRNA methyltransferase DNMT2 promotes hepatocellular carcinoma progression and enhances Bortezomib resistance through inhibiting TNFSF10. [Abstract]

2024 Nov 29:127:111533. PMID: 39617358
Mol Cell Biochem

A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling. [Abstract]

2024 Apr;479(4):843-857. PMID: 37204666

Bortezomib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 Apr;479(4):843-857. [Abstract]

Bortezomib (BTZ; 5, 10, 20 nM; 48 h) increases the expression level of γH2AX in RPMI-8226 and U266 cells.

Bortezomib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 Apr;479(4):843-857. [Abstract]

Bortezomib (BTZ; 10 nM; 48 h) significantly enhances the cell death of RPMI-8226.
Proteomes

Azidohomoalanine (AHA) Metabolic Labeling Reveals Unique Proteomic Insights into Protein Synthesis and Degradation in Response to Bortezomib Treatment. [Abstract]

2025 Nov 25;13(4):63. PMID: 41441334
Heliyon

Thrombospondin-1 induction and VEGF reduction by proteasome inhibition. [Abstract]

2023 Feb 1;9(2):e13397. PMID: 36846655
Epigenomes

Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay. [Abstract]

2026 Feb 23;10(1):14. PMID: 41892363
Exp Cell Res

KLF15-activated MARCH2 boosts cell proliferation and epithelial-mesenchymal transition and presents diagnostic significance for hepatocellular carcinoma. [Abstract]

2024 Jun 5:114117. PMID: 38848952
Exp Cell Res

BET inhibitors induce NF-κB and E2F downregulation in Hodgkin and Reed-Sternberg cells. [Abstract]

2023 Sep 15;430(2):113718. PMID: 37468057
Med Oncol

Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells. [Abstract]

2020 Nov 19;37(12):116. PMID: 33215275
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
ChemMedChem

Synthesis of Novel d-Glucopyranuronamide-Based Nucleos(t)ide Analogs Bearing (Triazolyl)methyl Phosph(on)ate Motifs With Anticancer and Antibacterial Potential. [Abstract]

2026 Jun 26;21(12):e70328. PMID: 42315993
J Immunol

Duck MARCH8 Negatively Regulates the RLR Signaling Pathway through K29-Linked Polyubiquitination of MAVS. [Abstract]

2023 Mar 15;210(6):786-794. PMID: 36715497
BMC Cancer

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells. [Abstract]

2021 Oct 13;21(1):1101. PMID: 34645397
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
BMC Cancer

Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells. [Abstract]

2018 Oct 11;18(1):971. PMID: 30309319

Bortezomib purchased from MedChemExpress. Usage Cited in: BMC Cancer. 2018 Oct 11;18(1):971. [Abstract]

The reduction of MAGEC2 protein level in TRIM28-knockdown A375 cells can be inhibited by treatment with both MG132 and PS-341, and similar result is also observed in Hs 695 T cells.
Chem Asian J

Selective Protein Degradation through Tetrazine Ligation of Genetically Incorporated Unnatural Amino Acids. [Abstract]

2024 Sep 2:e202400824. PMID: 39221720
J Cancer

Extrachromosomal circular DNA of multiple myeloma. [Abstract]

2025 Oct 1;16(14):4206-4218. PMID: 41210680
Cell Biol Int

Solute Carrier Family 19 Member 1 Mediates Acquired Bortezomib Resistance in Multiple Myeloma Through Chronic Stimulator of Interferon Genes Activation and Mitochondrial DNA Release. [Abstract]

2026 Feb;50(2):e70130. PMID: 41556422
Front Biosci (Landmark Ed)

Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma. [Abstract]

2024 Mar 15;29(3):106. PMID: 38538281
Funct Integr Genomics

SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer. [Abstract]

2023 May 5;23(2):147. PMID: 37145301
Am J Cancer Res

TAS-102 has a tumoricidal activity in multiple myeloma. [Abstract]

2020 Nov 1;10(11):3752-3764. PMID: 33294265
Mol Biol Rep

Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway. [Abstract]

2023 Sep;50(9):7457-7469. PMID: 37477799
Front Genet

The Prognostic Value and Function of HOXB5 in Acute Myeloid Leukemia. [Abstract]

2021 Aug 5:12:678368. PMID: 34421991
Vet Microbiol

The ubiquitin-proteasome system is essential for efficient propagation of Pseudorabies virus. [Abstract]

2025 Jun 13:307:110602. PMID: 40517584
PLoS One

Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma. [Abstract]

2022 Feb 14;17(2):e0263822. PMID: 35157705
Eur J Haematol

Junctional Adhesion Molecule-A (JAM-A) Associates With High-Risk Disease in Multiple Myeloma Patients and a Structure-Based Rationally-Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo. [Abstract]

2026 May 27. PMID: 42204384
Fungal Genet Biol

SsATG8 and SsNBR1 mediated-autophagy is required for fungal development, proteasomal stress response and virulence in Sclerotinia sclerotiorum. [Abstract]

2021 Dec:157:103632. PMID: 34710583
Biochem Biophys Res Commun

Evaluation of autophagy effector proteins for targeted protein degradation using chemically induced proximity. [Abstract]

2026 Jul 2:820:153847. PMID: 42054895
Oncol Lett

Bortezomib overcomes TRAIL resistance in Burkitt's lymphoma by enhancing apoptosis via reactive oxygen species-mediated DR5 upregulation and MAPK pathway activation. [Abstract]

2025 Oct 14;30(6):588. PMID: 41158317
Anticancer Drugs

APG-115 synergizes with bortezomib to induce apoptosis in cervical cancer cells. [Abstract]

2025 Jun 3. PMID: 40455647
Cell Div

Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K/AKT/RhoA signaling pathway in macrophages. [Abstract]

2025 Feb 14;20(1):5. PMID: 39953613
Biochem Biophys Res Commun

Rag GTPases suppress PRL-3 degradation and predict poor clinical diagnosis of cancer patients with low PRL-3 mRNA expression. [Abstract]

2021 Oct 22:576:108-116. PMID: 34482023
Biochem Biophys Res Commun

Bortezomib alleviates myocardial ischemia reperfusion injury via enhancing of Nrf2/HO-1 signaling pathway. [Abstract]

2021 Jun 4:556:207-214. PMID: 33848935
Biochem Biophys Res Commun

Proteasome inhibition promotes mono-ubiquitination and nuclear translocation of mature (52 kDa) PINK1. [Abstract]

2019 Sep 17;517(2):376-382. PMID: 31362890
Biochem Biophys Res Commun

The effects of cold atmospheric plasma on cell adhesion, differentiation, migration, apoptosis and drug sensitivity of multiple myeloma. [Abstract]

2016 May 13;473(4):1125-32. PMID: 27067049
Vet Comp Oncol

Auranofin Induces ER Stress-Mediated Apoptosis, and Its Combination With Bortezomib Elicits Paraptosis-Like Cell Death in Malignant Canine Mammary Tumour Cells. [Abstract]

2025 Apr 15. PMID: 40235190
J Biochem

Cytotoxic stress caused by azalamellarin D (AzaD) interferes with cellular protein translation by targeting the nutrient-sensing kinase mTOR. [Abstract]

2024 Jul 31;176(2):139-153. PMID: 38669682
Ir J Med Sci

PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling. [Abstract]

2023 Apr;192(2):561-567. PMID: 35508865
Biosci Biotechnol Biochem

Synergistic effect of cerium chloride and calcium chloride alters calcium signaling in keratinocytes to promote epidermal differentiation. [Abstract]

2024 Nov 22;88(12):1432-1441. PMID: 39333009
bioRxiv

2026 May 2.
Preprints

2026 May 8.
bioRxiv

2026 May 26.
bioRxiv

2026 Apr 5.
Res Sq

2026 Mar 10.
Charles University

2026.
bioRxiv

2026 Jan 6.
bioRxiv

Conformation-specific Antibody Deciphers K27-linked Ubiquitination in Chaperone-Mediated Proteostasis. [Abstract]

2025 Dec 18:2025.12.18.695067. PMID: 41446272
Stanford University

2025.
Seoul National University

2027.
University of Alberta

2027 Nov.
Harvard University

2025.
bioRxiv

2025 Oct 26.
bioRxiv

Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]

2025 Oct 9:2025.10.08.681217. PMID: 41279001
Authorea

2025 Oct 7.
bioRxiv

2025 Sep 29.
bioRxiv

Colorectal cancer-associated PCBP1 mutations disrupt protein stability in a dominant negative manner. [Abstract]

2025 Sep 25:2025.09.23.678070. PMID: 41040312
bioRxiv

Development of Degraders and 2-pyridinecarboxyaldehyde (2-PCA) as a recruitment Ligand for FBXO22. [Abstract]

2025 Aug 20:2025.08.19.671158. PMID: 40894587
bioRxiv

2025 Aug 06.
Res Sq

2025 Aug 05.
Res Sq

2025 Jul 24.
Patent

US20250129329A1.
bioRxiv

2025 April 27.
bioRxiv

2025 January 08.
Patent

US20240344035A1
Patent

US20240344035A1.
bioRxiv

2024 September 26.
bioRxiv

2024 Jul 25.
bioRxiv

Discovery of electrophilic degraders that exploit SNAr chemistry. [Abstract]

2024 Sep 27:2024.09.25.615094. PMID: 39386645
bioRxiv

Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. [Abstract]

2024 Aug 6:2024.03.21.586169. PMID: 38586030
bioRxiv

2024 September 10.
bioRxiv

2024 July 19.
Res Sq

2024 Jun 25.
bioRxiv

2024 July 04.
bioRxiv

2024 June 12.
bioRxiv

2024 May 14.
bioRxiv

2024 May 22.
Research Square Preprint

2024 Mar 29.
bioRxiv

Cytosolic Ribosomal Protein Haploinsufficiency affects Mitochondrial Morphology and Respiration. [Abstract]

2024 May 2:2024.04.16.589775. PMID: 38659761
Universidad de Navarra

2024 Feb 28.
bioRxiv

2024 Jan 7.
bioRxiv

2023 Oct 16.
University of Pardubice

2023 May 5.
Ruperto Carola University Heidelberg

2023 Jun 1.
University of Gothenburg

2023 Jun 27.
Oncotarget

LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair. [Abstract]

2023 Jun 12:14:597-611. PMID: 37306526
Research Square Preprint

2023 May 24.
Research Square Preprint

2023 May 25.
Research Square Preprint

2023 May 26.
Research Square Print

2023 Mar 24.
Patent

US20230073499A1.
Research Square Print

2023 Mar 22.
Research Square Print

2023 Feb 9th.
Research Square Print

2023 Feb 3.
Research Square Print

2023 Feb 3.
Authorea

2023 Jan 19.
bioRxiv

2022 Dec 21, 519945.
Patent

US20220054606A1.
bioRxiv

April 29, 2021.
Norwegian University of Science and Technology

2021 Oct.
Norwegian University of Science and Technology

2021 Oct.
Research Square Preprint

2021 Jul.
Patent

US20210023099A1.
Patent

US20180263995A1.
Patent

US20160222465A1.

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C)

DMSO : 50 mg/mL (130.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6025 mL

13.0127 mL

26.0254 mL

5 mM

0.5205 mL

2.6025 mL

5.2051 mL

10 mM

0.2603 mL

1.3013 mL

2.6025 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Konzentration

Volumen

Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution

Protocol 6

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 7

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 8

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 9

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: ≥ 0.5 mg/mL (1.30 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [Content Brief]

[2]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24. [Content Brief]

[3]. Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107(1):257-64. [Content Brief]

[4]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9. [Content Brief]

[5]. Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12(67):471-80. [Content Brief]

[6]. Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281(2):1107-18. [Content Brief]

[7]. Wang Y, et al. TREM2-Mediated Cholesterol Efflux in Macrophages Inhibits Anti-Tumor Immunity via Limitation of CD4+ T and NK Cells. Adv Sci (Weinh). 2025 Oct 20:e06995. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.6025 mL	13.0127 mL	26.0254 mL	65.0635 mL
	5 mM	0.5205 mL	2.6025 mL	5.2051 mL	13.0127 mL
	10 mM	0.2603 mL	1.3013 mL	2.6025 mL	6.5064 mL
	15 mM	0.1735 mL	0.8675 mL	1.7350 mL	4.3376 mL
	20 mM	0.1301 mL	0.6506 mL	1.3013 mL	3.2532 mL
	25 mM	0.1041 mL	0.5205 mL	1.0410 mL	2.6025 mL
	30 mM	0.0868 mL	0.4338 mL	0.8675 mL	2.1688 mL
	40 mM	0.0651 mL	0.3253 mL	0.6506 mL	1.6266 mL
	50 mM	0.0521 mL	0.2603 mL	0.5205 mL	1.3013 mL
	60 mM	0.0434 mL	0.2169 mL	0.4338 mL	1.0844 mL
	80 mM	0.0325 mL	0.1627 mL	0.3253 mL	0.8133 mL
	100 mM	0.0260 mL	0.1301 mL	0.2603 mL	0.6506 mL

Bortezomib

261 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bortezomib

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Targeted Therapy Drug Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Target Protein Ligand Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Boronic Acid Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Bortezomib

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle TREM receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (261)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs